Bluebird says gene therapy application delayed again, citing disagreement with FDA

Bluebird bio said Thursday it doesn't expect to complete an application for U.S. approval of its gene therapy LentiGlobin until mid-2021, as the biotech failed to reach agreement with the Food and Drug Administration about providing additional data for the agency's review.